Loading
FORT MYERS — NeoGenomics, a leading provider of cancer-focused genetic testing services, named Dr. Lawrence Weiss chief scientific officer. Weiss has served as medical director and laboratory director for NeoGenomics Laboratories since joining NeoGenomics as part of its acquisition of Clarient in 2015.
“Larry is a highly regarded thought leader in the oncology and pathology community, with years of medical and scientific leadership experience at NeoGenomics and other organizations,” says NeoGenomics Chairman and CEO Douglas VanOort in a statement. “Dr. Weiss is responsible for driving NeoGenomics scientific innovation initiatives and advancing our reputation in the oncology diagnostics community.”
Weiss holds a doctorate from the University of Maryland School of Medicine, where he received the Faculty Gold Medal for Outstanding Qualifications for the Practice of Medicine.
Prior to joining NeoGenomics, Weiss was laboratory director for Clarient Diagnostic Services and chairman of the Department of Pathology and Director of Laboratories for City of Hope National Medical Center in Duarte, Calif. Weiss is currently a visiting professor in the Department of Pathology and Medicine for the University of California at Irvine and is chairman emeritus of pathology at City of Hope.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
